Phenotypic associations of tau and ApoE in Parkinson's disease

Neuroscience Letters

Volumn 414, Issue 2, 2007, Pages 141-144

  Papapetropoulos, Spiridon ^a   Farrer, Matthew J ^b   Stone, Jeremy T ^b   Milkovic, Nicole M ^b   Ross, Owen A ^b   Calvo, Linda ^a   McQuorquodale, Donald ^a   Mash, Deborah C ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

ApoE; Association study; Dementia; Hallucinations; Phenotype; Post mortem; Tau

Indexed keywords

APOLIPOPROTEIN E; LEVODOPA; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DISEASE ASSOCIATION; DYSKINESIA; FEMALE; GENETIC POLYMORPHISM; GENETIC SCREENING; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRAIN; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HALLUCINATIONS; HUMANS; MALE; PARKINSON DISEASE; PHENOTYPE; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS;

EID: 33847071982     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.12.008     Document Type: Article

References (27)

1. Alim M.A., Ma Q.L., Takeda K., Aizawa T., Matsubara M., Nakamura M., Asada A., Saito T., Kaji H., Yoshii M., Hisanaga S., and Ueda K. Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein. J. Alzheimers Dis. 6 (2004) 435-442 (discussion 443-449)
2. Baker M., Litvan I., Houlden H., Adamson J., Dickson D., Perez-Tur J., Hardy J., Lynch T., Bigio E., and Hutton M. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 8 (1999) 711-715
3. Bonifati V., Joosse M., Nicholl D.J., Vanacore N., Bennett P., Rizzu P., Fabbrini G., Marconi R., Colosimo C., Locuratolo N., Stocchi F., Bonuccelli U., De Mari M., Wenning G., Vieregge P., Oostra B., Meco G., and Heutink P. The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases. Neurosci. Lett. 274 (1999) 61-65
4. Dickson D.W. Alpha-synuclein and the Lewy body disorders. Curr. Opin. Neurol. 14 (2001) 423-432
5. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7 (2006) 306-318
6. Farrer M., Skipper L., Berg M., Bisceglio G., Hanson M., Hardy J., Adam A., Gwinn-Hardy K., and Aasly J. The tau H1 haplotype is associated with Parkinson's disease in the Norwegian population. Neurosci. Lett. 322 (2002) 83-86
7. Frasier M., Walzer M., McCarthy L., Magnuson D., Lee J.M., Haas C., Kahle P., and Wolozin B. Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. Exp. Neurol. 192 (2005) 274-287
8. Galpern W.R., and Lang A.E. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann. Neurol. 59 (2006) 449-458
9. Giasson B.I., Forman M.S., Higuchi M., Golbe L.I., Graves C.L., Kotzbauer P.T., Trojanowski J.Q., and Lee V.M. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300 (2003) 636-640
10. Harhangi B.S., de Rijk M.C., van Duijn C.M., Van Broeckhoven C., Hofman A., and Breteler M.M. APOE and the risk of PD with or without dementia in a population-based study. Neurology 54 (2000) 1272-1276
11. Hoehn M.M., and Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 17 (1967) 427-442
12. Houlden H., Baker M., Morris H.R., MacDonald N., Pickering-Brown S., Adamson J., Lees A.J., Rossor M.N., Quinn N.P., Kertesz A., Khan M.N., Hardy J., Lantos P.L., St George-Hyslop P., Munoz D.G., Mann D., Lang A.E., Bergeron C., Bigio E.H., Litvan I., Bhatia K.P., Dickson D., Wood N.W., and Hutton M. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 56 (2001) 1702-1706
13. Huang X., Chen P., Kaufer D.I., Troster A.I., and Poole C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch. Neurol. 63 (2006) 189-193
14. Huang X., Chen P.C., and Poole C. APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology 62 (2004) 2198-2202
15. Hughes A.J., Daniel S.E., Ben-Shlomo Y., and Lees A.J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125 (2002) 861-870
16. Hughes A.J., Daniel S.E., Kilford L., and Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55 (1992) 181-184
17. Jensen P.H., Hager H., Nielsen M.S., Hojrup P., Gliemann J., and Jakes R. Alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J. Biol. Chem. 274 (1999) 25481-25489
18. Mahley R.W., Weisgraber K.H., and Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A 103 (2006) 5644-5651
19. Marder K., Maestre G., Cote L., Mejia H., Alfaro B., Halim A., Tang M., Tycko B., and Mayeux R. The apolipoprotein epsilon 4 allele in Parkinson's disease with and without dementia. Neurology 44 (1994) 1330-1331
20. Masliah E., Rockenstein E., Veinbergs I., Sagara Y., Mallory M., Hashimoto M., and Mucke L. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A 98 (2001) 12245-12250
21. Papapetropoulos S., Gonzalez J., Lieberman A., Villar J.M., and Mash D.C. Dementia in Parkinson's disease: a post-mortem study in a population of brain donors. Int. J. Geriatr. Psychiatry 20 (2005) 418-422
22. Papapetropoulos S., Lieberman A., Gonzalez J., and Mash D.C. Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease?. Acta. Neurol. Scand. 111 (2005) 353-359
23. Papapetropoulos S., McCorquodale D.S., Gonzalez J., Jean-Gilles L., and Mash D.C. Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations. Parkinsonism Relat. Disord. 12 (2006) 253-256
24. Rubinsztein D.C., and Easton D.F. Apolipoprotein E genetic variation and Alzheimer's disease. a meta-analysis. Dement. Geriatr. Cogn. Disord. 10 (1999) 199-209
25. Schmechel D.E., Saunders A.M., Strittmatter W.J., Crain B.J., Hulette C.M., Joo S.H., Pericak-Vance M.A., Goldgaber D., and Roses A.D. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A 90 (1993) 9649-9653
26. Spillantini M.G., and Goedert M. Tau and Parkinson disease. Jama 286 (2001) 2324-2326
27. Zhang J., Song Y., Chen H., and Fan D. The tau gene haplotype h1 confers a susceptibility to Parkinson's disease. Eur. Neurol. 53 (2005) 15-21